Explain this page
Arphra AIPlain-English read on Avis Budget Group, Inc.’s valuation06-04today
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma15h
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma15h
- Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection1d
- Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases5d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$971.01
+418.92% vs spot
Recommendation
Strong Buy
6 of 7 methods
Method spread
2bull4bear
±5% threshold
Analyst PT consensus: $128.17 (-31.50%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.31% | +3.38% | +25.79% | +85.80% | +42.81% | +45.82% | +46.71% | -7.62% | +104.28% | +496.30% | +9209.45% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$188.10
Bid
$185.00
5 sh
Ask
$191.65
230 sh
Spread
$6.650
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.53B | -$283M | $-8.02 |
| Q4 Dec 2025 | $2.66B | -$747M | $-21.22 |
| Q3 Sep 2025 | $3.52B | $359M | $10.11 |
| Q2 Jun 2025 | $3.04B | $4M | $0.11 |
| Q1 Mar 2025 | $2.43B | -$505M | $-14.35 |
| Q4 Dec 2024 | $2.71B | -$1.96B | $-55.66 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphomaglobenewswire.com·Jun 14, 2026
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphomaglobenewswire.com·Jun 14, 2026
- Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflectionseekingalpha.com·Jun 13, 2026
- Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseasesglobenewswire.com·Jun 09, 2026
- Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseasesglobenewswire.com·Jun 09, 2026
- Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nearsmarketbeat.com·Jun 09, 2026
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
Recent analyst activity
DB- Jun 08, 2026PT$160.00Barclays Upgrades Avis Budget Group (CAR) to EqualweightBarclays
Peers
No peer list available for CAR.
Total assets
$32.19B
Total debt
$31.17B
Cash & equiv
$519M
Operating CF
$3.3B
Free cash flow
-$11.98B
Buybacks
-$7M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $11.65B | $1.28B | -$889M | $-25.26 | -7.63% |
| FY 2024 | $11.79B | $1.5B | -$1.82B | $-51.23 | -15.45% |
| FY 2023 | $12.01B | $2.35B | $1.63B | $42.06 | +13.59% |
| FY 2022 | $11.99B | $3.28B | $2.76B | $57.11 | +23.04% |
| FY 2021 | $9.31B | $2.09B | $1.29B | $19.44 | +13.80% |